K P Zhidkov studies ulcerative colitis, which is a chronic condition causing inflammation in the digestive tract. Specifically, they investigate the effectiveness of propionyl-L-carnitine, a supplement that may help relieve symptoms in patients who are already receiving stable oral treatments. Their research aims to find ways to enhance patients' responses to treatment and improve their overall quality of life.
Key findings
In a clinical trial, 72% of patients taking propionyl-L-carnitine responded positively to treatment, compared to 50% in the placebo group.
The treatment was safe overall, with the majority of side effects being related to the stomach.
This research provides evidence that propionyl-L-carnitine could be a beneficial addition for managing symptoms of ulcerative colitis.
Frequently asked questions
Does Dr Zhidkov study ulcerative colitis?
Yes, Dr Zhidkov specifically focuses on ulcerative colitis and improving treatment options for patients.
What treatments has Dr Zhidkov researched?
Dr Zhidkov has researched the efficacy of propionyl-L-carnitine as a therapy for patients with ulcerative colitis.
Is Dr Zhidkov's work relevant to patients with ulcerative colitis?
Yes, their research directly addresses treatment improvements for patients suffering from ulcerative colitis.
Publications in plain English
Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment.
2011
Alimentary pharmacology & therapeutics
Mikhailova TL, Sishkova E, Poniewierka E, Zhidkov KP, Bakulin IG +15 more
Plain English In this study, researchers looked at the effects of propionyl-L-carnitine (PLC) on patients with mild-to-moderate ulcerative colitis (UC) who were already stable on treatment. They found that 72% of patients taking PLC had a positive response to treatment, compared to 50% in the placebo group, showing that PLC may help improve symptoms. The treatment was generally safe, with side effects mostly related to the stomach.
Who this helps: This helps patients with ulcerative colitis looking for better management options.
[Clinical pathomorphology of critical conditions].
2005
Arkhiv patologii
Rybakova MG, Zhidkov KP, Klechikov VZ
Plain English This paper reviews what happens to different organs, like the heart and lungs, when a patient is critically ill and dying. The authors explain that by clearly identifying the main health issues in autopsy reports, doctors can better understand how effective intensive care and emergency treatments are, which can lead to improved care in the future. This is important because it helps address the reasons why some treatments may not work.
Who this helps: This benefits doctors and patients in critical care situations.
[A case of respiratory distress syndrome complicated by the development of interstitial emphysema and pneumomediastinum].
2000
Anesteziologiia i reanimatologiia
Zhidkov KP, Bogatyr' MN, Chezhin AN, Leĭman VA, Smirnova OR
Plain English The study looked at a 15-year-old patient who was admitted to the ICU because of severe breathing problems caused by pneumonia. The patient was treated using a method called positive pressure ventilation, but this led to complications like air leaks in the lungs and chest. The findings highlighted unexpected pressures in the lungs, which helped doctors understand the effects of treatment on patients with serious respiratory issues.
Who this helps: This research helps doctors understand how to more effectively treat young patients with severe breathing difficulties.
[Experience in the treatment of severe forms of sepsis by extracorporeal therapy and hyperbaric oxygenation].
1997
Anesteziologiia i reanimatologiia
Zhidkov KP, Klechikov VZ, Bogatyr' MN
Plain English This study looked at 81 patients with severe sepsis and multiple organ failure to see if adding advanced treatments like extracorporeal therapy and hyperbaric oxygen helped improve outcomes. Among the 40 patients who received these additional treatments, the death rate dropped to 40%, compared to a shocking 94% in those who only received traditional care. This is important because it shows that these innovative therapies can significantly increase survival chances for critically ill patients.
Who this helps: This helps patients suffering from severe sepsis and their families.
Plain English This study examined how treating blood with a special material (hemosorbent) and returning it to patients with gastric ulcers affects their immune cells called lymphocytes. Among 114 patients, researchers found that there was a significant increase in the activity of these lymphocytes, which indicates that the treatment may help the body heal faster from ulcers. This is important because boosting the immune response can lead to quicker recovery.
Who this helps: Patients with gastric ulcers.
[The clinico-morphological characteristics of the gastric mucosa during peptic ulcer therapy with the autotransfusion of hemosorbent-treated blood].
1991
Terapevticheskii arkhiv
Zhidkov KP, Nutfullina GM
Plain English This study looked at 35 patients with chronic stomach ulcers to see how a treatment using their own blood (treated with a special method) affected the ulcers. After two weeks of treatment, 30 patients showed improvement with their ulcers either healing or becoming smaller. This finding is important because it indicates that this blood treatment can significantly help many patients with stomach ulcers.
Who this helps: This helps patients with chronic gastric ulcers.
[Dynamics of production of interleukin-1 by monocytes after hemosorption in patients with peptic ulcer].
1991
Vestnik khirurgii imeni I. I. Grekova
Ketlinskiĭ SA, Zhidkov KP, Pigareva NV
Plain English This study looked at how a treatment called hemosorption affects the production of a protein called interleukin-1 (IL-1) in patients with severe peptic ulcers. In 22 patients, those whose ulcers healed slowly showed no change in IL-1 production, but patients whose ulcers healed in more than two weeks had a significant increase in IL-1 after the treatment. This matters because higher IL-1 levels may help in the healing process of ulcers, potentially leading to better recovery outcomes.
Who this helps: This helps patients with peptic ulcers, particularly those facing slow healing.
Plain English This study looked at 52 patients with stomach ulcers that wouldn't heal and treated them by transfusing blood that was treated to remove harmful substances. After this treatment, 67% of the patients saw their ulcers start to heal within two weeks. The treatment helped boost certain enzymes in the immune cells, which likely helped remove dead tissue and speed up the healing of the ulcers.
Who this helps: This benefits patients with chronic stomach ulcers.
[Autotransfusions of sorbent blood in treating peptic ulcer patients with an unfavorable course].
1990
Vrachebnoe delo
Uspenskiĭ VM, Zhidkov KP, Malygin AM, Shevchenko EV
Plain English This study looked at how autotransfusions of treated blood helped 62 patients with difficult-to-treat gastric ulcers. The treatment led to healing in 70.9% of these patients and improved certain immune system functions. This is important because it provides a new way to help patients who struggle with severe ulcer issues.
Who this helps: Patients with gastric ulcers that are hard to treat.
[Changes in the natural killer activity of lymphocytes in peripheral blood of patients with purulent-septic diseases under the effect of extracorporeal perfusion of pig spleen sections].
1989
Anesteziologiia i reanimatologiia
Zhidkov KP, Malygin AM, Dmitriev NV, Borison AE, Shevchenko EV
Plain English Researchers studied 23 patients with severe infections that didn’t respond to standard treatments, using a procedure that involved perfusion with pig spleen tissue. Out of these patients, 17 experienced significant improvement in detoxifying their blood, while unfortunately, 6 patients died during the treatment. The procedure not only lowered certain harmful blood components but also restored the activity of natural killer cells, which play a crucial role in fighting infections, making this an important step in improving recovery for patients with these serious conditions.
Who this helps: This helps patients suffering from severe infections.
[A method of extracorporeal perfusion of the sections of xenogeneic spleen].
1989
Vestnik khirurgii imeni I. I. Grekova
Borisov AE, Zhidkov KP, Dmitriev NV, Domanskaia IA
Plain English Researchers developed a new method to use parts of pig spleens to treat patients with severe infections. They tested this method on 23 patients and found it to be effective, simple, and safe, using a small pump to circulate the solution through the spleen sections for 30 to 60 minutes. This study matters because it offers a potential new treatment option for patients facing life-threatening infections.
Who this helps: Patients with severe infections.
[Extracorporeal perfusion of the xenospleen in the treatment of suppurative surgical diseases].
1986
Vestnik khirurgii imeni I. I. Grekova
Zhidkov KP, Medvedev IuA, Dobrynskiĭ EK, Kopylov SM, Belova LA
Plain English This study looked at a treatment using pig spleen tissue to help five patients suffering from severe infections after surgery. Out of these patients, two showed signs of recovery, including one with a specific autoimmune disease affecting soft tissues. The researchers believe that using pig spleen in this way is an effective method for reducing toxins in patients dealing with septic complications.
Who this helps: This helps patients recovering from severe infections after surgery.